Clinical Trial Update: Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass [Phase 1]

View source ↗

Summary

Phase 1 safety trial of recombinant Factor XIII (rFXIII) in patients after first-time myocardial revascularization requiring cardiopulmonary bypass has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder

Drugs mentioned

• rFXIII (recombinant Factor XIII) (recombinant Factor XIII)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass | Phase 1 | Status: COMPLETED